Optimization of native E. coli-asparaginase therapy in standard risk-group children with acute lymphoblastic leukemia treated by the ALL-MB 2002 protocol

The paper presents the results of a multicenter randomized study of two-dose COLI-ASP regimens in therapy of consolidation of standard risk-group (SRG) children and adolescents with acute lymphoblastic leukemia (ALL) treated by the ALL-MB-2002 protocol. The principal aim of the study was to elucidat...

Full description

Saved in:

Bibliographic Details
Published in:	Onkogematologii͡a no. 3; pp. 25 - 33
Main Authors:	M. Yu. Goroshkova, Yu. V. Rumyantseva, O. V. Aleinikova, S. A. Dudkin, L. G. Fechina, A. V. Shamardina, O. V. Streneva, K. L. Kondratchik, L. M. Minkina, E. S. Lapotentova, E. V. Inyushkina, O. B. Kozlova, E. V. Zhukovskaya, O. P. Khlebnikova, E. V. Basharova, V. N. Timofeeva, G. P. Pavlova, V. D. Zlobina, O. A. Utrobina, E. S. Banshchikova, K. S. Aslanyan, E. V. Kondakova, E. V. Tselousova, N. V. Myakova, T. V. Turobova, O. V. Ryskal, O. Yu. Fuks, V. V. Lebedev, N. F. Chipsanova, S. R. Varfolomeeva, A. I. Karachunsky
Format:	Journal Article
Language:	Russian
Published:	ABV-press 01-11-2022
Subjects:	acute lymphoblastic leukemia children efficacy l-asparaginase toxicity
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The paper presents the results of a multicenter randomized study of two-dose COLI-ASP regimens in therapy of consolidation of standard risk-group (SRG) children and adolescents with acute lymphoblastic leukemia (ALL) treated by the ALL-MB-2002 protocol. The principal aim of the study was to elucidate whether the dose of COLI-ASP might be reduced without losing the efficiency of therapy. The analysis covered primary ALL patients notified at 36 clinics of Russia and Belarus, enrolled for the study in the period of May 1, 2002, to October 10, 2006. Out of 819 patients to be examined, 414 received COLI-ASP in a dose of 10,000 U/m2 (a control group), and 405 children took it in a dose of 5,000 U/m2 (a study group). No statistically significant differences were found between the patients in gender, age, baseline leukocytosis, and spleen size. The study showed no statistically and clinically significant differences in event-free, overall, and relapse-free survival (EFS, OS, and RFS, respectively) and relapse rates with the use of two-dose COLI-ASP regimens. However, in the control group, the death rate in remission was twice greater than that in the study group (p = 0.02). Detailed analysis of the outcomes of therapy in some subgroups revealed no differences between the control and study groups. The Cox multiple regression analysis has indicated that the factors influencing EFS and RFS are the baseline sizes of the spleen, baseline leukocytosis, age, and a response to treatment in the period of induction, rather than the dose of E. coli asparaginase. The authors have also found that among the SRG patients, there is a subgroup of patients without risk factors, in whom the reduction in the COLI-ASP dose may substantially increase survival rates, by lowering toxicity and mortality in remission.
ISSN:	1818-8346 2413-4023
DOI:	10.17650/1818-8346-2008-0-3-25-33